Surrozen, Inc.

NasdaqCM SRZN

Surrozen, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2024

Surrozen, Inc. Total Non-Current Liabilities is NA for the quarter ending September 30, 2024. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Surrozen, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2023 was USD 1.77 M, a -66.53% change year over year.
Surrozen, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2022 was USD 5.29 M, a -63.18% change year over year.
Surrozen, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2021 was USD 14.36 M.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

NasdaqCM: SRZN

Surrozen, Inc.

CEO	Mr. Craig C. Parker M.B.A.
IPO Date	Jan. 11, 2021
Location	United States
Headquarters	171 Oyster Point Boulevard
Employees	42
Sector	Healthcare
Industries Biotechnology Pharmaceuticals

Description

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Key trends

Past 5 years